Currently, 13 CAR-T treatments have received regulatory approval. Blood cancers have dominated the development pipeline of ...

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

Bi-Specific 3rd Generation CAR T therapy is a revolutionary advancement in cellular immunotherapy, primarily used to treat ...

Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.

The "Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering. The Chimeric Antigen Receptor T-Cell Therapy (CAR-T) ...

The following is a summary of “Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With ...

Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has ...